Effectiveness and safety of combined therapy versus monotherapy based on immune checkpoint inhibitors and/or targeted drugs as salvage treatment for advanced urothelial carcinoma: a systematic review and meta-analysis

被引:1
作者
Wei, Lichao [1 ]
Gao, Liang [1 ]
Hu, Zili [1 ]
Liu, Chuan [1 ]
机构
[1] Chongqing Med Univ, Dept Urol, Affiliated Hosp 2, 74 Linjiang Rd, Chongqing 400010, Peoples R China
关键词
Urothelial carcinoma (UC); salvage therapy; novel agents; combined therapy; monotherapy; PHASE-II TRIAL; OPEN-LABEL; 2ND-LINE TREATMENT; SINGLE-ARM; G-CSF; CANCER; MULTICENTER; PACLITAXEL; CHEMOTHERAPY; EVEROLIMUS;
D O I
10.21037/tcr-20-3354
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The standard salvage regimen for the patients with advanced urothelial carcinoma (UC) is uncertain, although lots of novel agents are recommended, including immune checkpoint inhibitors (ICIs) and targeted drugs (TDs). We aimed to compare the effectiveness and safety of combined therapy of novel agents (CNA) and monotherapy of novel agents (MNA) as salvage therapy for advanced UC. Methods: Studies exploring CNA and/or MNA for advanced UC in second-line setting were searched from PubMed, Embase, Cochrane Library, and Web of Science. The data of objective response rate (ORR), disease control rate (DCR), median progression-free survival (PFS), median overall survival (OS), and grade 3-4 adverse effects rate (grade 3-4 AEs%) were pooled for analyses. Cochrane risk of bias tool was applied for the quality judgment of randomized controlled studies (RCTs). Results: Forty-one arms from 37 studies including 4,691 patients were included. Significant differences were presented in pooled ORR (22.9% versus 12.2%, OR=1.88, P<0.001) and DCR (62.7% versus 37.5%, OR=2.53, P<0.001) between CNA and MNA groups. The pooled median PFS was 3.66 months in CNA group versus 2.16 months in MNA group (WMD=1.50, P=0.028). No significant difference in pooled median OS was found between two groups (7.93 versus 7.50 months, WMD=0.43, P=0.449). 63.7% versus 25.4% of pooled grade 3-4 AEs% could be seen in CNA and MNA groups (OR=3.52, P<0.001). Additionally, the pooled results of PFS-6m and OS-6m in CNA group demonstrated significant advantages over MNA group (31.5% versus 28.7%, OR=1.31, P=0.049; 66.0% versus 56.7%, OR=1.34, P=0.029, respectively). In the subgroup analysis of CNA, use of ICIs, the positive expression of PD-L1 and ECOG-PS=0 were significantly associated with superior clinical outcomes (P<0.05). Discussion: For advanced UC patients after first line agents, CNA had potential benefits than MNA in terms of ORR, DCR, median PFS, PFS-6m and OS-6m. However, CNA was associated with a significantly higher grade 3-4 AEs%. Furthermore, potential advantages were presented in CNA patients with ICIs usage, positive PD-L1 expression and ECOG-PS=0.
引用
收藏
页码:2091 / +
页数:22
相关论文
共 54 条
[1]   Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].
Apolo, Andrea B. ;
Infante, Jeffrey R. ;
Balmanoukian, Ani ;
Patel, Manish R. ;
Wang, Ding ;
Kelly, Karen ;
Mega, Anthony E. ;
Britten, Carolyn D. ;
Ravaud, Alain ;
Mita, Alain C. ;
Safran, Howard ;
Stinchcombe, Thomas E. ;
Srdanov, Marko ;
Gelb, Arnold B. ;
Schlichting, Michael ;
Chin, Kevin ;
Gulley, James L. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+
[2]   Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].
Balar, Arjun V. ;
Galsky, Matthew D. ;
Rosenberg, Jonathan E. ;
Powles, Thomas ;
Petrylak, Daniel P. ;
Bellmunt, Joaquim ;
Loriot, Yohann ;
Necchi, Andrea ;
Hoffman-Censits, Jean ;
Perez-Gracia, Jose Luis ;
Dawson, Nancy A. ;
van der Heijden, Michiel S. ;
Dreicer, Robert ;
Srinivas, Sandy ;
Retz, Margitta M. ;
Joseph, Richard W. ;
Drakaki, Alexandra ;
Vaishampayan, Ulka N. ;
Sridhar, Srikala S. ;
Quinn, David I. ;
Duran, Ignacio ;
Shaffer, David R. ;
Eigl, Bernhard J. ;
Grivas, Petros D. ;
Yu, Evan Y. ;
Li, Shi ;
Kadel, Edward E., III ;
Boyd, Zachary ;
Bourgon, Richard ;
Hegde, Priti S. ;
Mariathasan, Sanjeev ;
Thastrom, AnnChristine ;
Abidoye, Oyewale O. ;
Fine, Gregg D. ;
Bajorin, Dean F. .
LANCET, 2017, 389 (10064) :67-76
[3]   Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].
Bellmunt, J. ;
de Wit, R. ;
Vaughn, D. J. ;
Fradet, Y. ;
Lee, J. -L. ;
Fong, L. ;
Vogelzang, N. J. ;
Climent, M. A. ;
Petrylak, D. P. ;
Choueiri, T. K. ;
Necchi, A. ;
Gerritsen, W. ;
Gurney, H. ;
Quinn, D. I. ;
Culine, S. ;
Sternberg, C. N. ;
Mai, Y. ;
Poehlein, C. H. ;
Perini, R. F. ;
Bajorin, D. F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026
[4]   The pharmacological bases of the antiangiogenic activity of paclitaxel [J].
Bocci, Guido ;
Di Paolo, Antonello ;
Danesi, Romano .
ANGIOGENESIS, 2013, 16 (03) :481-492
[5]   Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway [J].
Boussiotis, Vassiliki A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) :1767-1778
[6]   Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer [J].
Choueiri, Toni K. ;
Ross, Robert W. ;
Jacobus, Susanna ;
Vaishampayan, Ulka ;
Yu, Evan Y. ;
Quinn, David I. ;
Hahn, Noah M. ;
Hutson, Thomas E. ;
Sonpavde, Guru ;
Morrissey, Stephanie C. ;
Buckle, Geoffrey C. ;
Kim, William Y. ;
Petrylak, Daniel P. ;
Ryan, Christopher W. ;
Eisenberger, Mario A. ;
Mortazavi, Amir ;
Bubley, Glenn J. ;
Taplin, Mary-Ellen ;
Rosenberg, Jonathan E. ;
Kantoff, Philip W. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) :507-512
[7]   Phase 2 Trial of Sorafenib in Patients With Advanced Urothelial Cancer A Trial of the Eastern Cooperative Oncology Group [J].
Dreicer, Robert ;
Li, Hailun ;
Stein, Mark ;
DiPaola, Robert ;
Eleff, Michael ;
Roth, Bruce J. ;
Wilding, George .
CANCER, 2009, 115 (18) :4090-4095
[8]  
Eum S, 2013, PROTECTIVE EFFECTS, V10, P101, DOI [10.21037/tcr-20-3354ofVitaminEonChemotherapy-InducedPeripheralNeuropathy:AMeta-AnalysisofRandomizedControlledTrials, DOI 10.21037/TCR-20-3354OFVITAMINEONCHEMOTHERAPY-INDUCEDPERIPHERALNEUROPATHY:AMETA-ANALYSISOFRANDOMIZEDCONTROLLEDTRIALS]
[9]   Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of &gt;2 years of follow-up [J].
Fradet, Y. ;
Bellmunt, J. ;
Vaughn, D. J. ;
Lee, J. L. ;
Fong, L. ;
Vogelzang, N. J. ;
Climent, M. A. ;
Petrylak, D. P. ;
Choueiri, T. K. ;
Necchi, A. ;
Gerritsen, W. ;
Gurney, H. ;
Quinn, D., I ;
Culine, S. ;
Sternberg, C. N. ;
Nam, K. ;
Frenkl, T. L. ;
Perini, R. F. ;
de Wit, R. ;
Bajorin, D. F. .
ANNALS OF ONCOLOGY, 2019, 30 (06) :970-976
[10]   Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer [J].
Gallagher, David J. ;
Milowsky, Matthew I. ;
Gerst, Scott R. ;
Ishill, Nicole ;
Riches, Jamie ;
Regazzi, Ashley ;
Boyle, Mary G. ;
Trout, Alisa ;
Flaherty, Anne-Marie ;
Bajorin, Dean F. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1373-1379